Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Metagenomi Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners. Although there are multiple examiners involved, the portfolio's active matters are concentrated within 2 distinct art units. This indicates that while individual examiners vary, the subject matter remains focused within a narrow range of specialized biotechnology groups at the patent office.
PAUL J HOLLAND is the busiest examiner for Metagenomi Inc., currently overseeing 1 pending office action. With pending office actions spread among distinct examiners, no single examiner holds a majority of the active workload. The distribution across the art units suggests that multiple examiners may be working within the same specialized group. This structure requires the company to manage relationships across multiple examiners while navigating the specific standards of the specialized art units. The presence of distinct examiners for the pending office actions ensures that each matter receives individual attention.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| MCLEOD, AFRICA MHAIRIE | 1 | 51.9% | +67.5% |
| MOAZZAMI, NAGHMEH NINA | 1 | 72.0% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18326440 | BASE EDITING ENZYMES | MCLEOD, AFRICA MHAIRIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18180633 | BASE EDITING ENZYMES | MOAZZAMI, NAGHMEH NINA | 9d |
| 18816810 | CLASS II, TYPE V CRISPR SYSTEMS | HOLLAND, PAUL J | — |
| 18326440 | BASE EDITING ENZYMES | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18816810 | CLASS II, TYPE V CRISPR SYSTEMS | HOLLAND, PAUL J | — | Other | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18326440 | BASE EDITING ENZYMES | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112 | Non-Final OA | — | Pending | May 31, 2023 |
| 18180633 | BASE EDITING ENZYMES | MOAZZAMI, NAGHMEH NINA | 1652 | §112Other | Final Rejection | 9d | Pending | Mar 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial